ARD:对系统性硬化症中纵向皮肤基因表达的大规模分析

2022-03-22 MedSci原创 MedSci原创

系统性硬化症 (SSc) 患者皮肤厚度与免疫细胞和成纤维细胞基因表达失调有关。在早期弥漫性SSc 中,皮肤基因表达随时间而变化,并趋于正常化。

    目的:系统性硬化症 (SSc) 患者的皮肤基因表达失调,但存在异质性。临床疾病特征与皮肤基因表达之间的关系尚未完全确定,并且个人体内皮肤基因表达随时间变化的程度尚不清楚。该研究目的在于确定皮肤基因表达与SSc临床疾病特征之间的关系,以及皮肤基因表达随时间的变化。

    方法:113SSc患者和44名匹配的健康对照中获得总共339份前臂皮肤活检。 105 SSc 患者进行了第二次活检,76 名进行了第三次活检。进行了全局基因表达谱分析,并评估了SSc中差异表达的基因和细胞类型特异性特征与改良的Rodnan皮肤评分 (mRSS) 和其他临床变量的关系。通过混合效应模型和主成分分析分析皮肤基因表达随时间的变化。进行免疫组织化学染色以验证结论。

     结果:SSc患者受累皮肤的基因表达失调比未受累皮肤的患者更严重。免疫细胞和成纤维细胞特征与 mRSS 呈正相关。随着时间的推移,高基线免疫细胞和成纤维细胞特征预测更高的mRSS,但在调整基线mRSS后不能独立预测纵向 mRSS在早期弥漫性皮肤 SSc中,免疫细胞和成纤维细胞特征随时间下降,整体皮肤基因表达趋于正常化。在免疫组织化学染色中,大多数具有高基线T细胞和巨噬细胞数量的早期弥漫性皮肤SSc患者在随访时这些数量有所下降。

     结论:SSc皮肤厚度与免疫细胞和成纤维细胞基因表达失调有关。在早期弥漫性SSc 中,皮肤基因表达随时间而变化,并趋于正常化。这些观察结果与了解 SSc 发病机制相关,可以为治疗策略和临床试验设计提供信息。

 

 

出处:Skaug B, Lyons MA, Swindell WR, et al. Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time. Annals of the Rheumatic Diseases 2022;81:516-523.

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1983225, encodeId=4c9c1983225ec, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Feb 27 08:52:56 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017355, encodeId=b88e201e3554d, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sun Aug 21 07:52:56 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043479, encodeId=f26020434e949, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue Aug 23 06:52:56 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348144, encodeId=1455134814498, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Mar 21 13:52:56 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627411, encodeId=ec2b162e41109, content=<a href='/topic/show?id=dbcee69217e' target=_blank style='color:#2F92EE;'>#系统性硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76921, encryptionId=dbcee69217e, topicName=系统性硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf521117287, createdName=yhy100207, createdTime=Mon Mar 21 13:52:56 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1983225, encodeId=4c9c1983225ec, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Feb 27 08:52:56 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017355, encodeId=b88e201e3554d, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sun Aug 21 07:52:56 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043479, encodeId=f26020434e949, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue Aug 23 06:52:56 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348144, encodeId=1455134814498, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Mar 21 13:52:56 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627411, encodeId=ec2b162e41109, content=<a href='/topic/show?id=dbcee69217e' target=_blank style='color:#2F92EE;'>#系统性硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76921, encryptionId=dbcee69217e, topicName=系统性硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf521117287, createdName=yhy100207, createdTime=Mon Mar 21 13:52:56 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1983225, encodeId=4c9c1983225ec, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Feb 27 08:52:56 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017355, encodeId=b88e201e3554d, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sun Aug 21 07:52:56 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043479, encodeId=f26020434e949, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue Aug 23 06:52:56 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348144, encodeId=1455134814498, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Mar 21 13:52:56 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627411, encodeId=ec2b162e41109, content=<a href='/topic/show?id=dbcee69217e' target=_blank style='color:#2F92EE;'>#系统性硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76921, encryptionId=dbcee69217e, topicName=系统性硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf521117287, createdName=yhy100207, createdTime=Mon Mar 21 13:52:56 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
    2022-08-23 ylz8403
  4. [GetPortalCommentsPageByObjectIdResponse(id=1983225, encodeId=4c9c1983225ec, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Feb 27 08:52:56 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017355, encodeId=b88e201e3554d, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sun Aug 21 07:52:56 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043479, encodeId=f26020434e949, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue Aug 23 06:52:56 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348144, encodeId=1455134814498, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Mar 21 13:52:56 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627411, encodeId=ec2b162e41109, content=<a href='/topic/show?id=dbcee69217e' target=_blank style='color:#2F92EE;'>#系统性硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76921, encryptionId=dbcee69217e, topicName=系统性硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf521117287, createdName=yhy100207, createdTime=Mon Mar 21 13:52:56 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1983225, encodeId=4c9c1983225ec, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Feb 27 08:52:56 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017355, encodeId=b88e201e3554d, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sun Aug 21 07:52:56 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043479, encodeId=f26020434e949, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue Aug 23 06:52:56 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348144, encodeId=1455134814498, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Mar 21 13:52:56 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627411, encodeId=ec2b162e41109, content=<a href='/topic/show?id=dbcee69217e' target=_blank style='color:#2F92EE;'>#系统性硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76921, encryptionId=dbcee69217e, topicName=系统性硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf521117287, createdName=yhy100207, createdTime=Mon Mar 21 13:52:56 CST 2022, time=2022-03-21, status=1, ipAttribution=)]

相关威廉亚洲官网

JCEM:皮肤高级糖基化终产物与肌肉减少症相关

较高的皮肤AGE与较高的肌肉减少症患病率相关。研究人员呼吁需要开展探索SAF作为肌肉减少症潜在生物标志物的纵向研究。

战“痘”不止丨解答常见5大问题,助你清爽战“痘”

虽说已经入秋,但仍然战“痘”不止。痘痘们就像约好了似的“此起彼伏”,再加上疫情的反扑,戴口罩出门已是常态,痘痘更是在脸上为非作歹!

LEO Pharma宣布FDA核准Adbry™ (tralokinumab)作为特异性靶向作用于中度至重度特应性皮炎成人IL-13的治疗药物

Adbry是LEO Pharma在美国上市的首个生物制剂,预计将于2022年2月在药店出售。 tralokinumab在美国以外的商品名是Adtralza®,目前已在欧盟、英国、加拿大和阿联酋获

文献解读:皮肤质量相关韩国研究-改善皮肤质量的行家:透明质酸

皮肤作为人体最大的器官覆盖全身,从美容和抗衰的角度出发,皮肤质量被看作为一个非常重要的因素,细腻、通透、水润的皮肤状态使得外表更加年轻化。

ARD:单细胞转录组分析可识别系统性硬化症中的皮肤特异性T细胞反应

尽管T细胞与系统性硬化症(SSc)的发病机制有关,但缺乏对进行性SSc患者受影响皮肤中T细胞介导的免疫反应的综合研究。该研究对SSc皮肤活检进行基于液滴的单细胞转录组分析。

非比寻常的“皮肤病”

学无止境,williamhill asia 仍需不断的学习知识和总结经验以帮助更多的患者。